ArticleJournal of hepatocellular carcinoma2025
Screening Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Patients After Tyrosine Kinase Inhibitor Plus PD-1/PD-L1 Antibody Therapy: A Multicenter Retrospective Study.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Conversion therapies after immune checkpoint inhibitors (ICIs) plus tyrosine-kinase inhibitors (TKIs) provide curative surgery chance and prolong survival for unresectable hepatocellular carcinoma (uHCC). However, only some patients have the opportunity to receive conversion therapies. To this end, we aimed to develop and validate a machine-learning model to identify patients who may have the chance to undergo conversion therapy. Methods: This retrospective cohort study included 443 patients with uHCC who received ICIs and TKIs from four centers. Variables were analyzed using univariate and multivariate logistic regression to identify independent indicators of conversion therapy. The Gradient Boosting Machine (GBM) algorithm was used to develop and validate model, and the Shapley additive explanation algorithm was used to mechanically explain the prediction of the model. Results: Overall, 84 (19%) patients underwent conversion therapy, and their prognosis were significantly longer than those did not ( Conclusion: The GBM-based combined model could identify patients who may benefit from conversion therapy for uHCC treated with ICIs and TKIs. Surgical resection as curative conversion therapy may provide better survival benefits than ablation therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.